GAP Ventures United States

Our team’s decades of experience and vast professional network can turn your company’s goals into reality. GAP Ventures provides “hands-on” support to facilitate the acquisition of investors, strategic partners and key customers in the U.S. and Canada.

We look for the strong fundamentals, good science and innovative technology, and work with  entrepreneurs and executive management to:

  • Identify U.S. market objectives and strategy with clear, value-creating milestones
  • Establish U.S. business registration and operations
  • Increase your network of contacts in the industry: pharma, medical device, diagnostics or health IT
  • Increase your network of investor contacts: angels, venture capital, investment bankers, and strategic partners.

GAP Ventures provides “on the ground’ resources to expand your business contacts and access key North American markets.

Ms Jennifer Seibert
CEO 

GCA Therapeutics United States

Corporate Overview

GCA Therapeutics Ltd (GCAT) is a US based, specialty pharmaceutical company focusing on in-licensing, acquisition and marketing of mid through late stage drug candidates and technologies from North America and the EU. GCAT applies its expertise and resources in pre-clinical, clinical, and final regulatory review and approval phases to commercialize products for use in the Chinese market. GCAT is currently in discussion with several US and European biotech and pharma firms to bring several important drugs to market through its joint venture in Tianjin, China. Initially, GCAT will market its products through a 3rd party distribution/sales partnership and will construct or acquire manufacture capabilities in China at a later date. GCAT currently has operations in New Jersey, New York, Shanghai, and Beijing.

Dr Mark Tang
Director 

GeneDX United States

GeneDx specializes in genetic testing for rare hereditary disorders. Our mission is to make clinical testing available to people with rare genetic conditions and their families. Most of our tests include full gene analysis by DNA sequencing, the gold standard of genetic testing. We invite you to explore our site, where you will find comprehensive information and all of our paperwork. Please note that GeneDx does not provide Direct-to-Consumer testing. All tests must be ordered, and results sent to a health care provider, usually a physician or genetic counselor. Families are encouraged to present our material to their health care providers who can evaluate the appropriateness of testing. For diagnostic testing in rare disorders, contact GeneDx… Where rare is common.

Dr Wendy Chung
MD  

GENEWIZ United States

GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory and clinical services. 

From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. 

At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. 

Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

Specialties

DNA Sequencing; Gene Synthesis; Mutation Analysis; SNP Discovery; Sequencing from Bacteria and Phage; Difficult Template Sequencing; Plasmid Preparation; Site-directed Mutagenesis; Fragment Analysis

Mr Steve Manobianco
Vice President 

Gibson Dunn & Crutcher LLP United States

From helping Tenet Healthcare stave off a hostile takeover to obtaining summary judgment for a former health care general counsel in a precedent-setting False Claims Act case to establishing ERISA preemption precedent in the United States Supreme Court on behalf of Aetna, achieving successful outcomes for our clients in their most important matters is our singular focus.

Mr Glenn Pollner
Partner 

GLG Pharma United States

GLG Pharma has been selected for the National Cancer Institute's Prevent Cancer development program. Click here for the most recent news. 

Cancer is a very complicated disease and no two cell cancers are similar but some generalizations of how this terrible disease progresses has been extensively studied and researched. This simple cartoon is meant to show just one pathway used by cancer cells to exploit the body's natural defensive mechanisms and reach a state of perptual immortality, allowing the cancer cells to grow, regardless of the consequences to the overall health of the host patient.

Mr Richard Gabriel
COO and Co-Founder 

GLOBAL CARE Initiative France

GLOBAL CARE Initiative is a French consortium of five non-profit Carnot research institutes dedicated to human health.

CALYM, the Consortium for the acceleration of innovation and its transfer to the field of Lymphoma
Curie Cancer, a component of Institut Curie focused on cancers
ICM, the Brain and Spine Institute dedicated to CNS diseases
Pasteur MI, the infectious diseases division of the Institut Pasteur
Voir et Entendre, expert in vision and audition diseases and rehabilitation

Our goal is to operate as a one-stop shop to life sciences companies and research and technological organizations that seek effective R&D partnerships. The Carnot Institutes can collaborate at any stage — from basic research to late clinical phases. GLOBAL CARE Initiative combines strong scientific expertise to unique technology platforms to propose an innovation-centered collaboration offer.

Specialties

CNS Diseases, Vision and Audition Diseases, Cancers, Lymphoma, Infectious Diseases

GLOBAL CARE Initiative GLOBAL CARE Initiative is a consortium of 5 French leading research institutes focused on infectious diseases (The institut Pasteur), oncology (The institut Curie), lymphoma (CALYM), vision and audition diseases (Voir et Entendre) and CNS (The brain and spine institute). Industry sectors All Therapeutics Area CNS-Neurology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Oncology
Ophthalmology
Rare Disease
Your innovative solution

The institutes have joined to combine their efforts in fostering their international research partnerships with the industry and other RTOs.

Which problem are you solving ?

The consortium operates as a one-stop-shop for life science companies and research organizations that seek R&D collaboration from basic research to the late clinical phases

Target market segments

Basic research / Preclinical research / Clinical

Key value proposition

One stop shop for all of the insitutes / Translational research collaborations (biobanks-clinical data/trials - Epidemiologic data - Animal/cells models) / Access to European market (Patient population/Cormecial market/ European KOLs/clinical centers)/New sourcing for innovation

Anne-C├ęcile Peras
USA East Coast Development 
Mr Etienne Bendjebbar
USA West Coast Development 

Global Orthopedic Network, Inc. United States

Mr Thomas Ferro
President 

GlobalData United States

Global research and consulting for the energy and healthcare industries

GlobalData is the premier source of actionable insight into the energy and healthcare industries. With the combined expertise of more than 1,000 researchers, market analysts and consultants, we provide high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

Combining precision with innovation, our research and consulting solutions ensure our clients stay at the forefront of their markets by integrating accurate market forecasts and analysis on the latest trends and developments with the unrivalled expertise of our analyst teams. Among other benefits, our informed industry perspectives help clients understand how to generate the maximum return from their key markets, identify opportunities from emerging trends, and devise strategies for growth with confidence.

Dr Peter Shapiro
Director 

GLUCK VENTURES LTD United States

Ms SUSAN FRIEDMAN
ASSET MANAGER